Prolactinomas
NEJM 362:1219-1226, Klibanski,A., 2010
Prolactinoma
NEJM 349:2035-2041, Schlechte,J.A., 2003
Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia
NEJM 349:2023-2033, Colao,A.,et al, 2003
SUNCT Syndrome in Two Patient with Prolactinomas and Bromocriptine-Induced Attacks
Neurol 58:1698-1699, Massiou,H.,et al, 2002
Management of Pituitary Tumors
Ann Int Med 129:472-483, Shimon,I.&Melmed,S., 1998
Diagnosis and Management of Hormone-Secreting Pituitary Adenomas
NEJM 324:822-831, Klibanski,A.&Zervas,N.T., 1991
Treatment of Prolactin-Secreting Pituitary Macroadenomas with the Long-Acting Non-Ergot Dopamine Agonist CV 205-502
Ann Int Med 112:668-673, Vance,M.L.,et al, 1990
Hyperprolactinaemia, Common and Treatable
BMJ 297:701-702, Hartog,M.&Hull,M.G.R., 1988
Giant Invasive Prolactinomas
Am J Med 83:995-1002, Murphy,F.Y.,et al, 1987
Prolactinomas
Editorial, BMJ 290:182-1841985., Grossman,A.,et al, 1985
Low Doses of Dopamine Agonists in the Long-Term Treatment of Macroprolactinomas
NEJM 313:656-659, Liuzzi,A.,et al, 1985
Cerebrospinal Fluid Rhinorrhea During Treatment with Bromocriptine for Prolactinoma
Neurol 35:1193-1195, Kok,J.G.,et al, 1985